Study on the effectiveness of fire suppression deluge systems in tunnels

The required water flow for adequate deluge system operation during a tunnel fire is currently only prescribed by a few regulatory authorities. Car fires are commonly used as references when addressing water-based suppression; nevertheless, limited public information exists on the amount of water required for correctly suppressing a car fire and the thresholds by which the suppression systems fails to be effective. This paper aims at delivering key experimental outcomes to fill this gap in car tunnel fire suppression. The effectiveness of deluge sprinkler systems was investigated by performing a series of full-scale car fire experiments. These experiments were performed by symmetrically positioning a single car under a single sprinkler nozzle, with activation happening (i.e. the sprinkler going off) at a certain time from ignition (which defines the size of the fire), and carefully gauging the burning behaviour of the car fire. A single car was used as it was deemed as the minimum unit for a fire. Temperatures inside, around, and above the car were measured and infrared camera footage was used to gauge flame heights during the experiment. Results from this study yielded two forms of car fire suppression by a deluge system: gradual and instantaneous. A correlation between heat release rate and required water flow for the deluge system is also presented. Outcomes herein show that a water flow per unit area of 6.6 mm/min is the minimum water flow required to effectively reduce the temperature in the immediate vicinity of a car fire of different sizes

Evaluation of Convalescent Plasma for Ebola Virus Disease in Guinea

: In the wake of the recent outbreak of Ebola virus disease (EVD) in several African countries, the World Health Organization prioritized the evaluation of treatment with convalescent plasma derived from patients who have recovered from the disease. We evaluated the safety and efficacy of convalescent plasma for the treatment of EVD in Guinea. : In this nonrandomized, comparative study, 99 patients of various ages (including pregnant women) with confirmed EVD received two consecutive transfusions of 200 to 250 ml of ABO-compatible convalescent plasma, with each unit of plasma obtained from a separate convalescent donor. The transfusions were initiated on the day of diagnosis or up to 2 days later. The level of neutralizing antibodies against Ebola virus in the plasma was unknown at the time of administration. The control group was 418 patients who had been treated at the same center during the previous 5 months. The primary outcome was the risk of death during the period from 3 to 16 days after diagnosis with adjustments for age and the baseline cycle-threshold value on polymerase-chain-reaction assay; patients who had died before day 3 were excluded. The clinically important difference was defined as an absolute reduction in mortality of 20 percentage points in the convalescent-plasma group as compared with the control group. : A total of 84 patients who were treated with plasma were included in the primary analysis. At baseline, the convalescent-plasma group had slightly higher cycle-threshold values and a shorter duration of symptoms than did the control group, along with a higher frequency of eye redness and difficulty in swallowing. From day 3 to day 16 after diagnosis, the risk of death was 31% in the convalescent-plasma group and 38% in the control group (risk difference, -7 percentage points; 95% confidence interval [CI], -18 to 4). The difference was reduced after adjustment for age and cycle-threshold value (adjusted risk difference, -3 percentage points; 95% CI, -13 to 8). No serious adverse reactions associated with the use of convalescent plasma were observed. : The transfusion of up to 500 ml of convalescent plasma with unknown levels of neutralizing antibodies in 84 patients with confirmed EVD was not associated with a significant improvement in survival. (Funded by the European Union's Horizon 2020 Research and Innovation Program and others; ClinicalTrials.gov number, NCT02342171.).<br/

Current achievements and future research directions in ovarian tissue culture, in vitro follicle development and transplantation: implications for fertility preservation

Female cancer patients are offered 'banking' of gametes before starting fertility-threatening cancer therapy. Transplants of fresh and frozen ovarian tissue between healthy fertile and infertile women have demonstrated the utility of the tissue banked for restoration of endocrine and fertility function. Additional methods, like follicle culture and isolated follicle transplantation, are in development. Specialist reproductive medicine scientists and clinicians with complementary expertise in ovarian tissue culture and transplantation presented relevant published literature in their field of expertise and also unpublished promising data for discussion. As the major aims were to identify the current gaps prohibiting advancement, to share technical experience and to orient new research, contributors were allowed to provide their opinioned expert views on future research. Normal healthy children have been born in cancer survivors after orthotopic transplantation of their cryopreserved ovarian tissue. Longevity of the graft might be optimized by using new vitrification techniques and by promoting rapid revascularization of the graft. For the in vitro culture of follicles, a successive battery of culture methods including the use of defined media, growth factors and three-dimensional extracellular matrix support might overcome growth arrest of the follicles. Molecular methods and immunoassay can evaluate stage of maturation and guide adequate differentiation. Large animals, including non-human primates, are essential working models. Experiments on ovarian tissue from non-human primate models and from consenting fertile and infertile patients benefit from a multidisciplinary approach. The new discipline of oncofertility requires professionalization, multidisciplinarity and mobilization of funding for basic and translational research

BELGIAN CANCER BAROMETER 2020 Methodology for the working groups

Introduction The Belgian Cancer Barometer 2020 (BCB2020) is a project commissioned and funded by the Belgian Foundation Against Cancer. The Belgian Cancer Centre of Sciensano is the project coordinator and works in close collaboration with the Belgian Cancer Registry and the College of Oncology. Although not a member of the Steering Committee, the Belgian Healthcare Knowledge Centre (KCE) is also involved in supporting the working groups with existing evidence collected by the KCE on economic evaluation. The BCB 2020 aims to provide a political and epidemiological state-of-play of cancer control in Belgium. The remaining challenges for patients, professionals and policy-makers will be identified and recommendations on how to overcome these challenges will be&nbsp;made. The BCB2020 will encompass five domains, also purpose of the five BCB2020 working&nbsp;groups: Health Promotion and Primary&nbsp;Prevention Screening and Early&nbsp;Detection Diagnosis and&nbsp;Treatment Survivorship and&nbsp;Rehabilitation Palliative&nbsp;care Four transversal topics will structure each&nbsp;domain: Epidemiological and political&nbsp;state-of-play Resources and&nbsp;costs Research and&nbsp;innovation Access/ equity/&nbsp;quality The inclusion of patient perception is key in identifying remaining challenges in cancer control in Belgium within the BCB2020. In providing an epidemiological and political state-of-play, an evidence-based approach (scientific justification) will be used and international comparisons will be made (European level). In addition to patients, other relevant stakeholders will be surveyed/ questioned on their perspectives concerning the previously stated domains and on their views on (remaining) challenges and possible recommendations. During three preliminary meetings and five preparatory meetings with members of the Steering Committee, the framework and objectives of the project have been discussed and agreed on. Following a close look at the scientifc literature and Belgian regulatory frameworks, the Steering Committee decided to focus on three aspects: an epidemiological and political state of play for each domain; the capture of the perspective of patients, relatives and the general public and, the formulation of recommendations to improve cancer control in Belgium (including the identification of needs for future research). Within a bit less than one year, experts (also including patients and informal caregivers?)/ experienced professionals in relevant fields of study/work will be invited to participate in working groups organized by domains and by topics within these domains. As for the final result of the project, a comprehensive report will be written mainly targetting policy-makers but also the general public as the reading&nbsp;audience.</p

Mesonephric adenocarcinoma of the cervix: Case report and literature review

A mesonephric adenocarcinoma of the cervix is a very rare tumor deriving from remnants of the mesonephric duct. Differential diagnosis from other cervical carcinomas is difficult and little is known regarding its biological behavior, prognosis, and the optimal management strategy. We present a case of a mesonephric adenocarcinoma of the cervix with a comprehensive review of the existing literature. In this case a 66-year-old woman presented with postmenopausal vaginal bleeding. She was diagnosed with a FIGO stage IIB mesonephric adenocarcinoma of the cervix and treated with neoadjuvant chemoradiotherapy and a Wertheim hysterectomy. The recovery from surgery was uneventful and the patient remains with no evidence of disease with 2 years of follow-up